Corcept Q1 revenue rises to $157.2 million; net income falls to $20.5 million
Corcept reported first quarter 2025 revenue of $157.2 million, up from $146.8 million a year earlier, but net income fell to $20.5 million and diluted earnings per share fell to $0.17 from $0.25. The company reiterated its 2025 revenue guidance of $900 million to $950 million and said a specialty pharmacy vendor's capacity limits hurt first quarter results.
Key points
- Revenue was $157.2 million versus $146.8 million in first quarter 2024.
- Operating expenses rose to $153.8 million from $117.3 million, with selling, general and administrative expenses at $90.7 million versus $56.3 million.
- 2025 revenue guidance of $900 million to $950 million was reiterated.
- Cash and investments were $570.8 million at March 31, 2025, down from $603.2 million at December 31, 2024.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.